May 16, 2018 - The following slide deck was published by Tesaro in conjunction with this event.
May 16, 2018 - Positive CHMP opinion on European approval.Approval in expanded label in USA.A 'bottoming out' of the stock.Comparison of PARPi sales.Maintaining our position in Clovis.
May 09, 2018 - Clovis (CLVS) witnesses wider year-over-year loss in the first quarter. However, the company's revenues beat estimates. Rubraca sales increase.
May 08, 2018 - Bb Biotech Ag Buys Tesaro Inc, argenx SE, Akcea Therapeutics Inc, Sells Juno Therapeutics Inc, Stocks: TSRO,AKCA,REGN,VYGR,ARGX,JUNO,, release date:May 08, 2018
May 07, 2018 - Lake Street issues rating change for TSRO
May 04, 2018 - The following slide deck was published by Tesaro in conjunction with their 2018 Q1 earnings call.
May 03, 2018 - TESARO Inc. (NASDAQ:TSRO) Q1 2018 Earnings Conference Call May 03, 2018 4:15 PM ET Executives Jennifer Davis – Vice President-Investor Relations and Corporate Communications Lonnie Moulder – Chief Exe
Apr 27, 2018 - AstraZeneca takes yet another hit in lung cancer immunotherapy.Tesaro's Zejula draws a new watermark for ovarian cancer.AveXis provides a glimpse into their pivotal trial in spinal muscular atrophy.
Apr 25, 2018 - Alder Biopharmaceuticals presented positive late-stage trial data.Centene reported outstanding Q1 revenues.Tesaro reports positive results from late-stage study of niraparib in ovarian cancer.
Apr 13, 2018 - Tesaro’s valuation is now on par with that of Clovis.Tesaro is pursuing a broad development program for niraparib in ovarian cancer, which, if executed appropriately, will provide significant competit